Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 184.82

-2.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (4279)	7/25/1997 6:58:00 PM
From: Henry Niman	of 32384

Sankyo is Japanese and they actually discovered Rezulin. They were also partners with GLYC and have taken an equity position in LGND (they are pursuing GLYC's inflammation program and are testing Galardin in Japan). Sankyo is definitely interested in TZDs and Rexinoids. They have there own TXD/PPAR program (as does GLX and LGND). On the Rezulin front, Sankyo sells it in Japan, WLA sells it in the U.S., and GLX and PFE sell it in Europe. LGND has stratgic alliance will all of the above (except WLA). I think that LGND will end up with a WLA and/or Sankyo deal for using Rexinoids to treat diabetes (and AGN may be involved also). The market is huge and expanding (may also have applications for athritis) and there's plenty of action for everyone. Henry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next